【Can-Fite BioPharma- Product CF102】Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Association of Liver Diseases (AASLD)

Partner News

24 Nov, 2020– Can-Fite BioPharma Ltd.
today announced that following a late-breaking oral presentation of its Phase
II Namodenoson study in the treatment of NAFLD/NASH delivered at the American
Association for the Study of Liver Diseases (AASLD) conference, the
presentation was selected as ‘Best of The Liver Meeting’ in the NAFLD/NASH
category and will be published in the summary slide deck. Inclusion in the Best
of the Liver Meeting is a singular honor and indicates the high level with
which the AASLD review committee regards the research.

were very pleased and honored that our Namodenoson NAFLD/NASH study results
received this recognition by the AASLD’s review committee, which is comprised
of thought leaders in liver disease. Our NASH program has generated strong
interest in science and business circles alike, as Namodenoson has shown the
potential to be a safe and effective treatment in a disease for which there is
currently no approved treatment. We believe inclusion in AASLD’s Best of the
Liver Meeting will further highlight our results in the medical community,”
said Can-Fite CEO Dr. Pnina Fishman.

The original website link: